TD Cowen initiated coverage of Simulations Plus (SLP) with a Hold rating and $16 price target The firm says the company’s software and services biosimulation platform drives significant cost and time savings for its biopharma customers. TD is “constructive” on the outlook for Simulations’ software revenue growth, but says a customer spending slowdown in the company’s consulting services “looms large” while synergies from its restructuring initiatives will take time.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SLP:
- S&P Dow Jones Indices announces quarterly rebalance
- Runway AI Expands Into Robotics Training With Nvidia and Alphabet Backing